Chan, J. K., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Cannon, T. L., Ahn, E. R., … Schilsky, R. L. (2024). Nivolumab plus ipilimumab (N plus I) in patients (pts) with solid tumors with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 42).

Chan, John K., Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Timothy Lewis Cannon, Eugene R. Ahn, Paul Swiecicki, et al. “Nivolumab plus ipilimumab (N plus I) in patients (pts) with solid tumors with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 42, 2024.

Chan JK, Rothe M, Mangat PK, Garrett-Mayer E, Cannon TL, Ahn ER, et al. Nivolumab plus ipilimumab (N plus I) in patients (pts) with solid tumors with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. In: JOURNAL OF CLINICAL ONCOLOGY. 2024.

Chan, John K., et al. “Nivolumab plus ipilimumab (N plus I) in patients (pts) with solid tumors with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 42, no. 16, 2024.

Chan JK, Rothe M, Mangat PK, Garrett-Mayer E, Cannon TL, Ahn ER, Swiecicki P, Hobbs E, Nazemzadeh R, Bell MC, Hosein PJ, Meric-Bernstam F, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Nivolumab plus ipilimumab (N plus I) in patients (pts) with solid tumors with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JOURNAL OF CLINICAL ONCOLOGY. 2024.